Som med anden medicin mod hiv kan patienter, der tager Reyataz, endvidere have risiko for at udvikle osteonekrose (henfald af knoglevæv) eller immunt reaktiveringssyndrom (infektionslignende symptomer, der skyldes, at immunsystemet genvinder sin funktion).
As with other anti-HIV medicines, patients taking Reyataz may also be at risk of osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).